There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
The FDA Drug Labels for allopurinol (PO) do not address this question.
From the Research
Discontinuation of Allopurinol in DLBCL Therapy
There is limited information available on when to discontinue allopurinol during Diffuse Large B-Cell Lymphoma (DLBCL) therapy. However, some studies provide insight into the management of DLBCL and the use of allopurinol in certain contexts:
- The use of allopurinol is mentioned in the context of treating acute tumor lysis syndrome (TLS) in patients with DLBCL, particularly those with end-stage renal disease (ESRD) 1.
- In the case of a hemodialysis patient with DLBCL, aggressive treatment with daily hemodialysis and allopurinol was beneficial 1.
- However, there is no specific guidance on when to discontinue allopurinol during DLBCL therapy, as the provided studies focus on the management of DLBCL, treatment outcomes, and novel therapies 2, 3, 4, 5.
- It is essential to consider the individual patient's condition, disease prognosis, and treatment plan when making decisions about discontinuing allopurinol or any other medication 2, 3, 4, 5.